REG - IQE PLC - Director/PDMR Shareholding

IqeAnnouncement

28/04/2022 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220428:nRSb7156Ja&default-theme=true

RNS Number : 7156J  IQE PLC  28 April 2022

IQE plc

 

Cardiff, UK

28 April 2022

 

Director/PDMR Shareholding

 

IQE plc (AIM:  IQE, "IQE" or the "Group"), the leading supplier of compound
semiconductor wafer products and advanced material solutions to the global
semiconductor industry, was notified on 27 April 2022 that on that date Dr
Drew Nelson, President and Non-Executive of the Company, purchased 250,000
ordinary shares of 1 pence each in the Company ("Ordinary Shares").

This announcement is made in accordance with Article 19 of the EU Market Abuse
Regulation 596/2014 (as incorporated into UK domestic law by the European
Union (Withdrawal) Act 2018).

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 1.  Details of the Person discharging managerial responsibilities ("PDMR") /
     person closely associated with them ("PCA")
 a)  Name                                     Dr Drew Nelson
 2.  Reason for the notification
 a)  Position / status                        PDMR (President and Non-Executive Director)
 b)  Initial notification / amendment         Initial notification

 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     IQE plc

 b)  Legal Entity Identifier                  213800Y33WHD3ESJJP16

 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary shares of 1 pence each in the Company

GB0009619924

 b)  Nature of the transaction                Purchase of Ordinary Shares

 c)  Price(s) and volume(s)                   250,000 Ordinary Shares at an average price of 30.2p per Ordinary Share
 d)  Aggregated information                   Aggregated volume: 250,000

     ·       Aggregated volume                Aggregated price: £75,500

     ·       Aggregated price
 e)  Date of the transaction(s)               27 April 2022

 f)  Place of the transaction                 London Stock Exchange, AIM (AIMX)

 

Contacts:

 

IQE plc

+44 (0) 29 2083 9400

Americo Lemos

Tim Pullen

Amy Barlow

 

Peel Hunt LLP (Nomad and Joint Broker)

+44 (0) 20 7418 8900

Edward Knight

Paul Gillam

James Smith

 

Citigroup Global Markets Limited (Joint Broker)

+44 (0) 20 7986 4000

Christopher Wren

Peter Catterall

 

Headland Consultancy (Financial PR)
+ 44 (0) 20 38054822

Andy Rivett-Carnac: +44 (0) 7968 997 365

Antonia Pollock: +44 (0) 7789 954 356

 

ABOUT IQE

http://iqep.com
(https://www.globenewswire.com/Tracker?data=yZf7NKp1JKLALUCxlBuC8wkLnLAqoe5-kjjIlkMIDci9q9W0x_02bwZV-eorSbpLXZxy4zi3xHh-O4FM8nWjeg==)

 

IQE is the leading global supplier of advanced compound semiconductor wafers
and materials solutions that enable a diverse range of applications across:

 

·    handset devices

·    global telecoms infrastructure

·    connected devices

·    3D sensing

 

As a scaled global epitaxy wafer manufacturer, IQE is uniquely positioned in
this market which has high barriers to entry. IQE supplies the whole market
and is agnostic to the winners and losers at chip and OEM level. By leveraging
the Group's intellectual property portfolio including know-how and patents, it
produces epitaxy wafers of superior quality, yield and unit economics.

IQE is headquartered in Cardiff UK, with c. 670 employees across nine
manufacturing locations in the UK, US, Taiwan and Singapore, and is listed on
the AIM Stock Exchange in London.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSEMSUAEESELL